A private investment firm based in USA makes co-investments into early stage life science companies. The firm prefers to invest in Series A-B rounds, and does not make seed investments. The firm makes investments of up to $300,000 out of the firm’s own capital, and is also working with an international partner that makes investments of up to $30 million in medical devices. The firm invests in startups US-wide.
The firm invests broadly in the life sciences and will consider opportunities in therapeutics, devices, diagnostics, healthcare IT and life science tools. The firm’s partner org is focused on late stage opportunities in the electronic medical device sector and will invest up to $30 million in these opportunities, with an interest in opportunities in which this org can act as a manufacturing partner. In other sectors, the firm makes early stage investments in companies that have established proof of concept, and interests include orphan drugs, the microbiome, healthcare data science, tools and some devices.
The firm prefers to invest in companies that have already received a significant round of funding in the past. For data and healthcare IT companies, initial revenues are preferred. The firm focuses on opportunities that will provide a short path to exit. The firm takes an active role with portfolio companies, particularly in making strategic and market connections with partners in Asia.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 